VR ADVISER LLC
Q2 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001615982
· CRD 169288
· SEC-registered investment adviser
$625.4M Reported Value Total
VENROCK ADVISER, LLC reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $2,417,300,965, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $4.5B gross asset value
Hedge Fund: $2.4B · Private Equity Fund: $2.1B
Source: Form ADV filed 2026-04-28
Reported value
$625.4M
Quarter over quarter
+10.6%
Holdings
30
Top-10 concentration
69.5%
Key People
Form ADV owners & control persons
Bong Young Koh
MEMBER
Bryan Edward Roberts
MEMBER
Jessica Tong Baron
CHIEF FINANCIAL OFFICER OF VENROCK ADVISER, LLC
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 11, 2023 |
| Form | 13F-HR |
| Reported value | $625.4M |
| Positions | 30 |
| Change in reported value | +22.1% |
| New positions | 10 |
| Exited positions | 5 |
| Position turnover | 42.9% |
| Top-10 concentration | 69.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
33 | $3.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
33 | $2.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
27 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
33 | $1.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
31 | $1.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
37 | $1.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
37 | $1.5B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
38 | $1.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $1.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
38 | $2.1B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
36 | $1.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
37 | $949.9M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
30 | $625.4M |
|
Q1 2023 13F
Filed May 15, 2023
|
25 | $512.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
28 | $593.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
31 | $648.1M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
27 | $507.8M |
|
Q1 2022 13F
Filed May 16, 2022
|
27 | $617.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
26 | $731.5M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
26 | $778.5M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | VRDN VIRIDIAN THERAPEUTICS INC | $73.3M | 11.73% |
| 2 | COGT COGENT BIOSCIENCES INC | $55.5M | 8.87% |
| 3 | FDMT 4D MOLECULAR THERAPEUTICS IN | $54.2M | 8.67% |
| 4 | ELVN ENLIVEN THERAPEUTICS INC | $45.5M | 7.28% |
| 5 | MRUS MERUS N V | $45.5M | 7.27% |
| 6 | GHRS GH RESEARCH PLC | $41.7M | 6.67% |
| 7 | AMAM AMBRX BIOPHARMA INC | $40.9M | 6.54% |
| 8 | KALV KALVISTA PHARMACEUTICALS INC | $26.3M | 4.2% |
| 9 | TERN TERNS PHARMACEUTICALS INC | $26.0M | 4.16% |
| 10 | CABA CABALETTA BIO INC | $25.5M | 4.07% |
| 11 | DYN DYNE THERAPEUTICS INC | $24.5M | 3.91% |
| 12 | CELC CELCUITY INC | $23.1M | 3.7% |
| 13 | SVRA SAVARA INC | $20.3M | 3.25% |
| 14 | PHVS PHARVARIS N V | $20.1M | 3.21% |
| 15 | RYTM RHYTHM PHARMACEUTICALS INC | $18.0M | 2.87% |
| 16 | ORIC ORIC PHARMACEUTICALS INC | $16.6M | 2.66% |
| 17 | ACRS ACLARIS THERAPEUTICS INC | $10.8M | 1.73% |
| 18 | TRVI TREVI THERAPEUTICS INC | $8.2M | 1.31% |
| 19 | APLT APPLIED THERAPEUTICS INC | $7.2M | 1.16% |
| 20 | THRX THESEUS PHARMACEUTICALS INC | $7.2M | 1.15% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.